0566015 - ÚMG 2023 RIV US eng J - Článek v odborném periodiku
Ryšánek, David - Vašicová, Pavla - Kolla, Jayaprakash Narayana - Sedlák, David - Anděra, Ladislav - Bártek, Jiří - Hodný, Zdeněk
Synergism of BCL-2 family inhibitors facilitates selective elimination of senescent cells.
Aging. Roč. 14, č. 16 (2022), s. 6381-6414. ISSN 1945-4589. E-ISSN 1178-1998
Grant CEP: GA MŠMT(CZ) LM2018129; GA MŠMT(CZ) EF18_046/0016045; GA ČR(CZ) GA18-14259S; GA MŠMT(CZ) LM2018130; GA MŠMT LX22NPO5102
Institucionální podpora: RVO:68378050
Klíčová slova: homoharringtonine * cellular senescence * bcl-2 * mcl-1 * senolytics
Obor OECD: Cell biology
Impakt faktor: 5.2, rok: 2022 ; AIS: 1.087, rok: 2022
Způsob publikování: Open access
Web výsledku:
https://www.aging-us.com/article/204207/textDOI: https://doi.org/10.18632/aging.204207

Accumulation of senescent cells in tissues with advancing age participates in the pathogenesis of several human age-associated diseases. Specific senescent secretome, the resistance of senescent cells to apoptotic stimuli, and lack of immune system response contribute to the accumulation of senescent cells and their adverse effects in tissues. Inhibition of antiapoptotic machinery, augmented in senescent cells, by BCL-2 protein family inhibitors represents a promising approach to eliminate senescent cells from tissues. This study aimed to explore synergistic and selective senolytic effects of anti-apoptotic BCL-2 family targeting compounds, particularly BH3 mimetics.
Trvalý link: https://hdl.handle.net/11104/0337451